Author:
Raut Jiko,Sarkar Olivia,Das Tanmoy,Mandal Santi M.,Chattopadhyay Ansuman,Sahoo Prithidipa
Abstract
AbstractMethotrexate (MTX), an efficient chemotherapy medication is used in treating various malignancies. However, the breast cancer cell line MDA-MB-231 has developed resistance to it due to low levels of the MTX transport protein, and reduced folate carrier (RFC), making it less effective against these cancer cells. Here we designed a very simple, biocompatible, and non-toxic amine-capped ZnO quantum dots to overcome the MTX resistance on the MDA-MB-231 breast cancer cell line. The QD was characterized by HRTEM, DLS EDX, FT-IR, UV–Vis, and Fluorescence spectroscopy. MTX loading onto the QD was confirmed through fluorescence and UV–Vis spectroscopy. Additionally, extensive confocal microscopic investigations were carried out to determine whether the MTX was successfully released on the MDA-MB-231 cell line. It was discovered that QD is a better pH-responsive delivery system than the previous ones because it successfully delivers MTX to the MDA-MB-231 at a higher rate on an acidic pH than it does at a physiological pH. QD also has anticancer activity and can eradicate cancer cells on its own. These factors make the QD to be an effective pH-responsive delivery system that can improve the efficacy of the medication in therapeutic diagnosis.
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Chen, S. et al. Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int. J. Oncol. 45, 448–458 (2014).
2. Bukowski, K., Kciuk, M. & Kontek, R. Mechanisms of multidrug resistance in cancer chemotherapy. Int. J. Mol. Sci. 21, 3233 (2020).
3. Cai, X., Luo, Y., Zhang, W., Du, D. & Lin, Y. pH-sensitive ZnO quantum dots-doxorubicin nanoparticles for lung cancer targeted drug delivery. ACS Appl. Mater. Interfaces 8(34), 22442–22450 (2016).
4. Lindgren, M. et al. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. BiochemPharmacol. 71(4), 416–425 (2006).
5. Gorlick, R. et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. N. Engl. J. Med. 335(14), 1041–1048 (1996).